The FDA approved the gene therapy Zolgensma to treat children with a severe form of spinal muscular atrophy. The drug costs $2.125 million for a one-time treatment, CBS News reported.
from WebMD Health https://ift.tt/2ZFHnVR
The FDA approved the gene therapy Zolgensma to treat children with a severe form of spinal muscular atrophy. The drug costs $2.125 million for a one-time treatment, CBS News reported.
Another 61 probable cases of the disease have been identified, according to Nancy Nydam, director of communications at Georgia Department of Public Health, CNN reported.

Ten British women have undergone a first-of-a-kind surgery that could delay menopause by up to 20 years.
The U.S. Preventive Services Task Force (USPSTF) on Tuesday reaffirmed its prior recommendation against routine screening for pancreatic cancer.